Elicio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elicio Therapeutics (ELTX).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$15Upside to Avg. PT+672.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	B. Riley Securities	Mayank Mamtani	PT Cut	Buy	$27→$8
Aug 18, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$23
Jun 18, 2026	Ladenburg Thalmann	Kevin DeGeeter	Assumes	Buy	$12
Jun 16, 2026	Jones Trading	Boris Peaker	Downgrade	Buy→Hold	—
Jun 15, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$17→$23
Jun 10, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$27
May 28, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$17
Apr 15, 2026	Ladenburg Thalmann	Aydin Huseynov	Initiate	Buy	$20
Mar 13, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$13→$17
Mar 10, 2026	Rodman & Renshaw	Michael King	Initiate	Buy	$17
Jul 17, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$10→$13
Apr 2, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$10
Oct 31, 2024	Jones Trading	Soumit Roy	Initiate	Buy	$9
Aug 23, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$10
Jun 6, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$10
May 22, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$10
May 1, 2024	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$11→$10
Apr 1, 2024	Oppenheimer	Matthew Biegler	Maintained	Perform	—
Jan 17, 2024	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$10→$11
Oct 26, 2023	HC Wainwright & Co.	Robert Burns	Assumes	Buy	$12

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.

Benzinga Newsdesk

PRO
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Jones Trading Downgrades Elicio Therapeutics to Hold

Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $17 to $23.

Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27

B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $27.

Benzinga Newsdesk

Elicio Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Elicio Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

PRO
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

PRO
Jones Trading Downgrades Elicio Therapeutics to Hold

PRO
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

PRO
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27

People Also Watch

People Also Watch

Elicio Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Elicio Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

PROHC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

PROLadenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

PROJones Trading Downgrades Elicio Therapeutics to Hold

PROHC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

PROB. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27

People Also Watch

People Also Watch

PRO
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

PRO
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

PRO
Jones Trading Downgrades Elicio Therapeutics to Hold

PRO
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

PRO
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27